Navigation Links
ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
Date:9/9/2008

$38,282,000 $43,790,000

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $4,186,000 $2,074,000

Other current liabilities 2,589,000 2,233,000

Total current liabilities 6,775,000 4,307,000

Long-term liabilities 982,000 1,671,000

Stockholders' equity 30,525,000 37,812,000

$38,282,000 $43,790,000

THERMOGENESIS CORP.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended Years Ended

June 30, June 30,

2008 2007 2008 2007

Net revenues $7,182,000 $3,520,000 $21,946,000 $16,751,000

Cost of revenues 4,832,000 2,596,000 14,976,000 11,554,000

Gross profit 2,350,000 924,000 6,970,000 5,197,000

Expenses:

Selling, general

and

administrative 2,838,000 2,817,000 10,165,000 9,630,000

Research and

development 2,157,000 1,139,000 7,172,000 4,108,000

Total operating

expenses 4,995,000 3,956,000 17,337,000 13,738,000

Interest and other

income, net 161,000 419,000 1,186,000 1,765,000

Net loss ($2,484,000) ($2,613,000) ($9,181,000) ($6,776,000)

Basic and diluted

net loss per

common share ($0.04) ($0.05) ($0.16) ($0.12)

Shares used in

computing

per share data 55,956,452 55,369,291 55,754,578 55,169,977

THERMOGENESIS CORP.<
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6